JP2015508284A5 - - Google Patents

Download PDF

Info

Publication number
JP2015508284A5
JP2015508284A5 JP2014548019A JP2014548019A JP2015508284A5 JP 2015508284 A5 JP2015508284 A5 JP 2015508284A5 JP 2014548019 A JP2014548019 A JP 2014548019A JP 2014548019 A JP2014548019 A JP 2014548019A JP 2015508284 A5 JP2015508284 A5 JP 2015508284A5
Authority
JP
Japan
Prior art keywords
amino acid
seq
nucleic acid
homodimeric protein
acid molecule
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2014548019A
Other languages
English (en)
Japanese (ja)
Other versions
JP2015508284A (ja
JP6258864B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2012/076404 external-priority patent/WO2013092875A1/en
Publication of JP2015508284A publication Critical patent/JP2015508284A/ja
Publication of JP2015508284A5 publication Critical patent/JP2015508284A5/ja
Application granted granted Critical
Publication of JP6258864B2 publication Critical patent/JP6258864B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2014548019A 2011-12-21 2012-12-20 Hpvに対するワクチン Active JP6258864B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161578542P 2011-12-21 2011-12-21
US61/578,542 2011-12-21
PCT/EP2012/076404 WO2013092875A1 (en) 2011-12-21 2012-12-20 Vaccines against hpv

Publications (3)

Publication Number Publication Date
JP2015508284A JP2015508284A (ja) 2015-03-19
JP2015508284A5 true JP2015508284A5 (enExample) 2016-02-18
JP6258864B2 JP6258864B2 (ja) 2018-01-10

Family

ID=47471832

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2014548019A Active JP6258864B2 (ja) 2011-12-21 2012-12-20 Hpvに対するワクチン

Country Status (17)

Country Link
US (1) US9901635B2 (enExample)
EP (2) EP3533462A1 (enExample)
JP (1) JP6258864B2 (enExample)
KR (1) KR102057265B1 (enExample)
CN (1) CN104039833B (enExample)
AU (1) AU2012356969B2 (enExample)
BR (1) BR112014015016B1 (enExample)
CA (1) CA2858963C (enExample)
DK (1) DK2793937T3 (enExample)
ES (1) ES2730718T3 (enExample)
HU (1) HUE043361T2 (enExample)
IL (1) IL233217B (enExample)
PT (1) PT2793937T (enExample)
RU (1) RU2644201C2 (enExample)
TR (1) TR201908199T4 (enExample)
WO (1) WO2013092875A1 (enExample)
ZA (1) ZA201404516B (enExample)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2970466A1 (en) * 2013-03-15 2016-01-20 Vaccibody AS Targeting vaccines for veterinary use
WO2015106281A1 (en) * 2014-01-13 2015-07-16 Baylor Research Institute Novel vaccines against hpv and hpv-related diseases
CN107073070A (zh) 2014-08-15 2017-08-18 格纳西尼有限公司 治疗宫颈癌的方法
HK1252967A1 (zh) * 2015-08-20 2019-06-06 Janssen Vaccines & Prevention B.V. 治疗性hpv18疫苗
JP2019505512A (ja) * 2016-01-08 2019-02-28 バッシボディ アクスイェ セルスカプ 治療用抗癌ネオエピトープワクチン
EP3678699A1 (en) * 2017-09-07 2020-07-15 University Of Oslo Vaccine molecules
EP3678698A1 (en) 2017-09-07 2020-07-15 University Of Oslo Vaccine molecules
WO2021205027A1 (en) 2020-04-09 2021-10-14 Vaccibody As Individualized therapeutic anticancer vaccine
MX2022013063A (es) 2020-04-24 2022-12-08 Genexine Inc Metodo para tratamiento del cancer cervicouterino.
US20230165952A1 (en) 2020-05-01 2023-06-01 Nykode Therapeutics ASA Betacoronavirus prophylaxis and therapy
AU2022244191A1 (en) 2021-03-26 2023-09-28 Nykode Therapeutics ASA Therapeutic combination for treating cancer
WO2022233851A1 (en) 2021-05-03 2022-11-10 Nykode Therapeutics ASA Immunogenic constructs and vaccines for use in the prophylactic and therapeutic treatment of infectious diseases
WO2022238363A1 (en) 2021-05-10 2022-11-17 Nykode Therapeutics ASA Immunogenic constructs and vaccines for use in the prophylactic and therapeutic treatment of infectious diseases
EP4337247A1 (en) 2021-05-10 2024-03-20 Nykode Therapeutics ASA Tolerance-inducing constructs and compositions and their use for the treatment of immune disorders
WO2022238381A2 (en) 2021-05-10 2022-11-17 Nykode Therapeutics ASA Immunotherapy constructs for treatment of disease
IL308310A (en) 2021-05-10 2024-01-01 Nykode Therapeutics ASA Co-expression of immune-stimulating structures and compounds
WO2022238432A2 (en) 2021-05-10 2022-11-17 Nykode Therapeutics ASA Co-expression of constructs and immunoinhibitory compounds
KR20240007235A (ko) 2021-05-10 2024-01-16 니코데 테라퓨틱스 에이에스에이 관용-유도 컨스트럭트 및 조성물 및 면역 장애의 치료를 위한 그들의 용도
EP4426344A1 (en) 2021-11-03 2024-09-11 Nykode Therapeutics ASA Immunogenic constructs and vaccines for use in the prophylactic and therapeutic treatment of diseases caused by sars-cov-2
WO2024092025A1 (en) 2022-10-25 2024-05-02 Nykode Therapeutics ASA Constructs and their use
US20260193669A1 (en) 2022-11-09 2026-07-09 Nykode Therapeutics ASA Co-Expression of Constructs and Polypeptides

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9105383D0 (en) * 1991-03-14 1991-05-01 Immunology Ltd An immunotherapeutic for cervical cancer
AUPN015794A0 (en) 1994-12-20 1995-01-19 Csl Limited Variants of human papilloma virus antigens
CA2499837C (en) 2002-10-03 2013-12-03 Wyeth Holdings Corporation Human papillomavirus polypeptides and immunogenic compositions
AU2004215489B2 (en) 2003-02-25 2010-07-15 Nykode Therapeutics ASA Modified antibody
PL1576967T3 (pl) * 2004-03-18 2008-03-31 Pasteur Institut Rekombinowane białko niosące epitopy ludzkiego wirusa brodawczaka wstawione w białko cyklazy adenylanowej lub jego fragment oraz jego zastosowania terapeutyczne
WO2006081323A2 (en) 2005-01-26 2006-08-03 The Johns Hopkins University Anti-cancer dna vaccine employing plasmids encoding mutant oncoprotein antigen and calreticulin
WO2011161244A1 (en) 2010-06-25 2011-12-29 Vaccibody As Homodimeric protein constructs

Similar Documents

Publication Publication Date Title
RU2014129788A (ru) Вакцины против hpv
CN108434450B (zh) 基于铁蛋白纳米颗粒的疫苗及其制备方法
JP2013532971A5 (enExample)
Liu et al. High immunogenic enterovirus 71 strain and its production using serum-free microcarrier Vero cell culture
JP2012095652A5 (enExample)
JP6974358B2 (ja) Hpv l2ペプチドの免疫原性の改善
RU2013103335A (ru) Конструкции гомодимерных белков
EP3199545A3 (en) Computationally optimized broadly reactive antigens for h1n1 influenza
WO2008098484A1 (en) Recombinant l1 proteins of human papilloma virus and uses thereof
JP2019506175A5 (enExample)
JP2010166921A5 (enExample)
RU2677799C2 (ru) Модифицированные суперспиральные белки с улучшенными свойствами
JP2014534202A5 (enExample)
CN104710515B (zh) 人乳头瘤病毒l1蛋白突变体及其制备方法
AR045804A1 (es) Expresion optimizada de l1 del vph45 en levaduras
JP2015501840A5 (enExample)
JP2012515557A5 (enExample)
JP2014519817A5 (enExample)
JP2026500600A (ja) Hpv感染関連疾患を予防又は治療するためのポリヌクレオチド分子
JP2021516991A5 (enExample)
CN105296521A (zh) 表达可溶性人乳头瘤病毒16亚型l1蛋白的重组质粒及其表达方法
JP2014530224A (ja) ノロウイルス感染に対するワクチンとしての自己集合ペプチドナノパーティクル
JP2013531991A5 (enExample)
JP2019502404A5 (enExample)
JP2010538619A5 (enExample)